Dr. Michael Rahman Shafique, MD

Dr. Shafique practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Shafique's NPI, 1992096028, was assigned on April 24, 2011. Dr. Shafique graduated from UVA School of Medicine in 2011. Dr. Shafique holds Florida license ME119260.

Dr. Shafique's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Shafique's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Shafique to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shafique practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Shafique's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Shafique is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Shafique's licenses on file in 2 states: Florida and North Carolina.

Dmand AI lists breast cancer, lung cancer and lymphoma among the conditions Dr. Shafique treats.

CMS data shows 602 Medicare services from Dr. Shafique across 5 procedure codes in 2024, for 273 Medicare patients. Medicare paid $54,965 for them.

CMS counts 273 Medicare patients who saw Dr. Shafique in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have cancer, and 75% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shafique's median patient age at 69, with 66% women.

In 2024, Dr. Shafique wrote 1,226 Medicare Part D claims for 214 patients. 73% of them were for generic drugs. CMS names the drug for 958 of them, across 28 drugs with 11 or more claims each, at $4,082,355 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Shafique for performance year 2024, reported as part of a group. Dr. Shafique accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shafique as offering telehealth.

Dmand AI links 23 papers to Dr. Shafique, published from 2013 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Shafique has published most often in Int J Radiat Oncol Biol Phys. Dr. Shafique's most frequent co-authors are Tawee Tanvetyanon, Alberto A. Chiappori, MD and Jhanelle E. Gray, MD.

Dmand AI links Dr. Shafique to 9 clinical trials, 5 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4.

CMS Open Payments shows 7 general payments to Dr. Shafique from 2 drug and device companies from 2024 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Roche Diagnostics Corporation paid the most, $4,248.

Dmand AI lists 1 award for Dr. Shafique, most recently AOA Inductee 2011 in 2011.

Dr. Shafique graduated from UVA School of Medicine in 2011. Dr. Shafique is a member of AOA.

Dr. Shafique is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.